Advanced Accelerator Application SA(ADR) Stock

Equities

End-of-day quote Nasdaq Other stock markets
-	-

2017	Advanced Accelerator Application : Novartis to buy French cancer specialist AAA for $3.9 billion	RE
2017	Advanced Accelerator Application : Novartis to buy French cancer specialist AAA for $3.9 billion	RE

Advanced Accelerator Application : Novartis to buy French cancer specialist AAA for $3.9 billion	17-11-03	RE
Advanced Accelerator Application : Novartis to buy French cancer specialist AAA for $3.9 billion	17-10-30	RE
Advanced Accelerator Application : Novartis to buy France's Advanced Accelerator for $3.9 billion	17-10-30	RE

Advanced Accelerator Applications signs exclusive option and license agreement with FUJIFILM Toyama Chemical to develop and commercialize radiolabeled FF-10158 for oncology indications	18-12-03	GL
Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer	18-02-12	GL
Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer	18-02-01	GL
Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors	18-01-26	GL
Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer	18-01-22	GL

Novartis : Le conseil d'administration d'AAA recommande l'offre de 3,9 mds de dollars de Novartis	17-12-06
Advanced Accelerator Application : Novartis offre 3,9 milliards de dollars pour le français Advanced Accelerator	17-10-30
WDH/Novartis will US-Unternehmen Advanced Accelerator Applications übernehmen	17-10-30
Novartis : compte acquérir Advanced Accelerator Applications pour 3,9 mds de dollars	17-10-30
Novartis : compte acquérir Advanced Accelerator Applications pour 3,9 mds de dollars	17-10-30

Managers	Title	Age	Since
Caio Kugelmas DFI	Director of Finance/CFO	-	-
Sidonie Roswitha Golombowski-Daffner CHM	Chairman	-	19-09-30
Ute Simon CTO	Chief Tech/Sci/R&D Officer	-	20-03-31

Members of the board	Title	Age	Since
Frédéric Collet BRD	Director/Board Member	-	17-12-31
Jessica Toepfer BRD	Director/Board Member	-	17-12-31
Sidonie Roswitha Golombowski-Daffner CHM	Chairman	-	19-09-30

Sector

	1st Jan change	Capi.
MERCK KGAA	+4.86%	70.36B
KYOWA KIRIN CO. LTD.	+12.11%	9.26B
SK BIOPHARMACEUTICALS CO., LTD.	-16.73%	4.72B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+23.84%	3.89B
YUHAN CORPORATION	+1.45%	3.75B
INDIVIOR PLC	+29.79%	2.66B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-24.17%	2.37B
BETTA PHARMACEUTICALS CO., LTD.	-27.04%	2.17B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	-3.78%	1.75B